Sherbrooke Park Advisers LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sherbrooke Park Advisers LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,004 shares of the biopharmaceutical company's stock, valued at approximately $1,428,000. Regeneron Pharmaceuticals comprises approximately 0.5% of Sherbrooke Park Advisers LLC's investment portfolio, making the stock its 15th biggest position.

Other large investors have also modified their holdings of the company. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Private Wealth Management Group LLC increased its position in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. UBS Group reduced their price target on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Finally, StockNews.com cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $890.60.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $14.84 during mid-day trading on Wednesday, hitting $599.95. 469,789 shares of the company's stock traded hands, compared to its average volume of 791,408. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a 50 day simple moving average of $596.79 and a two-hundred day simple moving average of $679.72. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The stock has a market cap of $64.77 billion, a price-to-earnings ratio of 15.67, a P/E/G ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the company earned $9.55 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.